- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06232408
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants With Advanced Solid Tumors
Study Overview
Detailed Description
This is a first-in-human, Phase 1, multi-center, open-label, dose-escalation and expansion study to:
Evaluate the safety profile and MTD of RP-1664 and establish a recommended dose and schedule for further clinical investigation, In addition, the study aims to characterize the PK, PD, and preliminary anti-tumor activity of orally administered RP-1664. Exploratory objectives include examination of biomarker responses in relationship to RP-1664 exposure.
After the recommended dose and schedule is determined, expansion cohorts with molecularly selected advanced solid tumors will be enrolled to preliminarily assess the anti-tumor effect, and further examine the safety and PK of RP-1664 at the RP2D.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Gabriela Gomez, MD
- Phone Number: 857-340-5402
- Email: clininfo@reparerx.com
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Participating Site 1008
-
Contact:
- Gabriela Gomez
- Phone Number: 857-340-5402
- Email: clininfo@reparerx.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent or assent, according to local guidelines, signed and dated by the patient or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses.
- Male or female and ≥ 12 years-of-age at the time of signature of the consent or assent, and are at least 6th grade reading level to consent; participants < 18 years of age must weigh at least 40 kg.
- Life expectancy ≥ 4 months.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Locally advanced or metastatic solid tumor that has progressed or was nonresponsive or intolerant to available therapies and for which no standard or available curative therapy exists.
- Measurable disease as per RECIST v1.1 or INRC.
- Existing biomarker profile (tumor tissue or plasma) reported from a local test obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarkers.
- Available tumor tissue.
- Molecularly eligible tumor profile from a CLIA-certified pathology report.
- Ability to comply with the protocol and study procedures detailed in the Schedule of Assessments.
- Ability to swallow and retain oral medications.
- Acceptable organ function at screening.
- Acceptable blood counts at screening.
- Negative pregnancy test (serum or urine) for females of childbearing potential at Screening and while on study drug.
- Resolution of all toxicities of prior treatment or surgery.
- Use of highly effective forms of contraception.
Exclusion Criteria:
- History or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the patient's safety.
- Uncontrolled, symptomatic brain metastases.
- Presence of other known second malignancy with the exception of any cancer that has been in complete remission for ≥ 2 years or completely resected squamous and basal cell carcinomas of the skin.
- Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
- Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions, active or within 6 months prior to enrollment.
- Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).
- Uncontrolled high blood pressure.
- Chemotherapy, small molecule or biologic antineoplastic agent given within 21 days.
- Previously prescribed receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor initiated less than 4 months prior to trial entry. Bisphosphonates are allowed if initiated/administered at least 28 days prior to enrollment.
- I-131 Meta-Iodo-Benzyl-Guanidine (MIGB) therapy within 6 weeks prior to initiation of trial treatment.
- Prior treatment with a PLK4 inhibitor.
- Current treatment with medications that are known to prolong the QT interval.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RP-1664
|
RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed per NCI CTCAE v5.0 criteria
Time Frame: From start of study intervention up to 90 days after last administration
|
From start of study intervention up to 90 days after last administration
|
Dose Limiting Toxicities to determine a maximum tolerated dose and schedule of RP-1664 based on safety and tolerability as measured by CTCAE v5.0, pharmacokinetic parameters, pharmacodynamic readouts and efficacy data per RECIST or INRC criteria
Time Frame: Up to 90 days after last administration of study intervention
|
Up to 90 days after last administration of study intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the PK parameters of RP-1664 in the fed and fasted states by measurement of plasma concentrations of RP-1664 with calculation of maximum observed plasma concentration (Cmax).
Time Frame: Through Study Day 114
|
Through Study Day 114
|
To assess the preliminary anti-tumor activity of RP-1664 in participants with molecularly selected advanced solid tumors treated at pharmacologically active dose ranges. Anti-tumor activity will be measured by ORR according to RECIST 1.1 and INRC.
Time Frame: About 36 months
|
About 36 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-1664-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
GI Innovation, Inc.RecruitingAdvanced Solid Tumor | Metastatic Solid TumorKorea, Republic of, United States
-
Xenthera, Inc.Not yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on RP-1664
-
Ewha Womans UniversityCompletedOsteoarthritisKorea, Republic of
-
European Organisation for Research and Treatment...RecruitingAll Tumor TypesSpain, United Kingdom, Croatia, Belgium, France, Netherlands, Italy, Germany, Portugal, Austria, Cyprus, Czechia, Estonia, Greece, Lithuania, Poland, Romania, Slovenia, Switzerland, Serbia
-
Repare TherapeuticsDebiopharm International SARecruitingAdvanced Solid TumorUnited States, Canada, Denmark
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedObsessive-Compulsive DisorderUnited States
-
DePuy InternationalTerminated
-
Rocket Pharmaceuticals Inc.RecruitingPKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)United States
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group AUnited States
-
Rocket Pharmaceuticals Inc.California Institute for Regenerative Medicine (CIRM)CompletedLeukocyte Adhesion Defect - Type ISpain, United States, United Kingdom
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group ASpain
-
Rocket Pharmaceuticals Inc.WithdrawnLeukocyte Adhesion Defect - Type ISpain